References
- Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer 1996;74:1929–1934.
- Endo K, Maehara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 1996;68:372–377.
- Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996;32A:912–920.
- Narasaki F, Matsuo I, Ikuno N, Fukuda M, Soda H, Oka M. Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res 1996;16:2079–2082.
- Nooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 1996;7:75–81.
- Cass CE, Janowska-Wieczorek A, Lynch MA, Sheinin H, Hindenburg AA, Beck WT. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. Cancer Res 1989;49:5798–5804.
- Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf JM, Levy SB. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res 1994;54:5607–5613.
- Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081–2087.
- Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002;64:573–582.
- Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 2007;296:85–95.
- Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 2008;259:111–118.
- Zhang LK, Hou SX, Zhang JQ, Hu WJ, Wang CY. Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles. Arch Pharm Res 2010;33:1193–1198.
- Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 2011;7:1–10.
- Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond) 2007;2:219–232.
- Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine 2009;5:323–333.
- Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 2010;6:662–671.
- Kohl Y, Kaiser C, Bost W, Stracke F, Fournelle M, Wischke C et al. Preparation and biological evaluation of multifunctional PLGA-nanoparticles designed for photoacoustic imaging. Nanomedicine 2011;7:228–237.
- Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002;79:123–135.
- Duan Y, Sun X, Gong T, Wang Q, Zhang Z. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. J Mater Sci Mater Med 2006;17:509–516.
- Chen Y, Wang F, Benson HA. Effect of formulation factors on incorporation of the hydrophilic peptide dalargin into PLGA and mPEG-PLGA nanoparticles. Biopolymers 2008;90:644–650.
- Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 2009;5:410–418.
- Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm 2003;259:115–127.
- Chen Y, Wang F, Benson HA. Effect of formulation factors on incorporation of the hydrophilic peptide dalargin into PLGA and mPEG-PLGA nanoparticles. Biopolymers 2008;90:644–650.
- Song X, Zhao Y, Hou S, Xu F, Zhao R, He J et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008;69:445–453.
- Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm 2008;350:320–329.
- Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvand R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine 2007;3:161–167.
- Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005;290:137–144.
- Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005;26:1009–1016.